Business
INVO Selects Kansas City as additional INVO Center Location
U.S. Market Expansion Continues as Planned SARASOTA, Fla., April 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("INVO" or the "Company"), a
About this update from Invo Fertility, Inc.
[{"type":"text","content":"U.S. Market Expansion Continues as Planned\nSARASOTA, Fla., April 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) (\"INVO\" or the \"Company\"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (\"IVC\") procedure it enables, today announced plans to open an INVO Center in Kansas City, Missouri. The Kansas City INVO Center will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell® solution. The Company currently has three operational INVO Centers treating patients in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico, with others scheduled to open in the San Francisco and Tampa areas.\n\n \n \n \n \n \n \n\n \n\"We are excited to announce Kansas City as another ideal location for an INVO Center,\" commented Steve Shum, CEO of INVO. \"We are refining the process involved in opening an INVO Center and are executing these initiatives simultaneously to improve operational timelines and revenue ramp. This new INVO Center is consistent with our stated expansion plans and represents a key component of our strategy to expand access to advanced fertility services for the significantly underserved patient population in the U.S. and abroad.\"\nThe Company evaluates several criteria and data points as part of its efforts to identify markets suitable for INVO Centers. Based on an analysis of current population statistics, we believe that Kansas City may have upwards of 33,000 patients suffering with Infertility. With an estimated 1,500 IVF treatments annually, there exists a large gap of available care to treat local demand. Similar to other INVO Centers, the Company expects to engage physician partners to support its efforts in the Kansas City market.\nAbout INVO Bioscience\nWe are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology (\"ART\") marketplace by making fertility care accessible and inclusive to people around the world. Our flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable...